• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    I-Mab ADR (NQ: IMAB )

    1.430 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 1.430
    Bid (Size) 1.400 (3)
    Ask (Size) 1.580 (3)
    Prev. Close 1.430
    Today's Range 1.430 - 1.430
    52wk Range 1.170 - 3.038
    Shares Outstanding 185,613,662
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
    Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
    Via Talk Markets
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -36.44%
    -36.44%
    1 Month
    -14.88%
    -14.88%
    3 Month
    -20.56%
    -20.56%
    6 Month
    -14.37%
    -14.37%
    1 Year
    -49.47%
    -49.47%

    More News

    Read More
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    (IMAB) - Analyzing I-MAB's Short Interest
    Via Benzinga
    NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    Looking Into I-MAB's Recent Short Interest
    Via Benzinga
    Expert Ratings for I-MAB
    Via Benzinga
    Where I-MAB Stands With Analysts
    Via Benzinga
    Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
    Via Talk Markets
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Week In Review: Two China Biopharmas Announce Billion Dollar Deals
    Via Talk Markets
    Week In Review: Adlai Nortye Stages $97.5 Million US IPO On Nasdaq
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    Analyst Ratings for I-MAB
    Via Benzinga
    5 Analysts Have This to Say About I-MAB
    Via Benzinga
    I-Mab Reveals Promising Results in Phase 1b/2 Study for Advanced Non-Small Cell Lung Cancer Treatment
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
    Via Talk Markets
    7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole
    Via InvestorPlace
    Why Is TRACON Pharma (TCON) Stock Down 51% Today?
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Last Day Of Q1
    Via Benzinga
    ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
    Via Benzinga
    Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.